210
Participants
Start Date
May 5, 2023
Primary Completion Date
April 8, 2026
Study Completion Date
May 23, 2026
WJB001
"Dose Escalation:~Accelerated titration (the first two dose groups) and BOIN combination (the subsequent dose group) were used for dose escalation.~Dose Expansion:~Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D.~Cohort Expansion:~The preliminary plan of cohort expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts."
RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
RECRUITING
Liaoning Cancer Hospital, Shenyang
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Henan Cancer Hospital, Henan
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Tumor Hospital Affiliated to Guangxi Medical University, Nanning
RECRUITING
The First Affiliated Hospital of Xi 'an Jiaotong University, Xi’an
RECRUITING
Shanxi Cancer Hospital, Taiyuan
Sponsor GmbH
OTHER
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
INDUSTRY